贝伐珠单抗在复发性卵巢癌中的应用。

Bevacizumab in recurrent ovarian cancer.

机构信息

Akdeniz University, Department of Obstetrics and Gynecology, Division of Gynecologic Oncology. Antalya, Turkey.

出版信息

J BUON. 2021 Jul-Aug;26(4):1271-1278.

Abstract

PURPOSE

The cost-effectiveness of bevacizumab has been the subject of debate, and we aimed to present our own retrospective data on its effect on survival in recurrent epithelial ovarian cancer.

METHODS

Patients with recurrent ovarian, tubal and primary peritoneal cancer between October 2007 and June 2018 were grouped according to the platinum-free interval. The progression-free and overall survivals of the patients who had received chemotherapy only and chemotherapy with bevacizumab were calculated.

RESULTS

Eighty patients had received chemotherapy (CT) only, and 65 had received CT+BV. In platinum-sensitive recurrent epithelial ovarian cancer (PSREOC) patients, the median progression-free survival (PFS) months was 7 months (95% CI; 5.5-8.4) in the group who had received CT only and 13 months (95% CI; 5.8-20.1) in the group who had received CT+BV (p=0.001) and for CT+BV HR (Hazard Ratio):0.39 (95% CI; 0.24-0.64) (p=0.001). The median PFS of platinum-resistant recurrent epithelial ovarian cancer (PRREOC) patients who had received CT only was determined as 2 (95% CI; 1.4-2.5) and as 10 (95% CI; 6.8-13.1) months for patients who had received CT+BV (p=0.001), for patients who had received CT+BV HR: 0.31 (95% CI; 0.17-0.58) (p=0.001). In both PSREOC and PRREOC patients, there was no difference between CT + BV and CT group in terms of overall survival (p=0.978 and p=0.738, respectively).

CONCLUSION

A significant effect of bevacizumab on the progression-free survival of both platinum-sensitive and platinum resistant recurrent ovarian cancers has been demonstrated; however, this effect failed to impact overall survival. Therefore, it could be recommended to use bevacizumab, considering the cost-effectiveness in undeveloped and developing countries.

摘要

目的

贝伐珠单抗的成本效益一直存在争议，我们旨在介绍我们自己关于其在复发性上皮性卵巢癌生存方面影响的回顾性数据。

方法

根据无铂间期将 2007 年 10 月至 2018 年 6 月间患有复发性卵巢、输卵管和原发性腹膜癌的患者分为两组。仅接受化疗和化疗联合贝伐珠单抗治疗的患者的无进展生存期和总生存期进行了计算。

结果

80 例患者仅接受化疗（CT），65 例患者接受 CT+BV。在铂敏感复发性上皮性卵巢癌（PSREOC）患者中，仅接受 CT 治疗的患者中位无进展生存期（PFS）为 7 个月（95%CI；5.5-8.4），而接受 CT+BV 治疗的患者中位 PFS 为 13 个月（95%CI；5.8-20.1）（p=0.001），CT+BV 的 HR（风险比）为 0.39（95%CI；0.24-0.64）（p=0.001）。仅接受 CT 治疗的铂耐药复发性上皮性卵巢癌（PRREOC）患者的中位 PFS 为 2 个月（95%CI；1.4-2.5），而接受 CT+BV 治疗的患者中位 PFS 为 10 个月（95%CI；6.8-13.1）（p=0.001），接受 CT+BV 的患者 HR 为 0.31（95%CI；0.17-0.58）（p=0.001）。在 PSREOC 和 PRREOC 患者中，CT+BV 组与 CT 组在总生存期方面无差异（p=0.978 和 p=0.738）。